Pall Corporation, RoosterBio Collaborate
News Oct 08, 2016
Pall Corporation has announced the signing of a commercial collaboration agreement with RoosterBio Inc. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). These systems will enable the BioPharmaceutical industry to accelerate product development, reduce clinical translation timelines and ultimately streamline the commercialization pathway for stem cell-based therapies.
Pall Life Sciences has continued expanding their Cell Therapy Manufacturing solutions portfolio, and this partnership furthers that aim. The complementary tools that RoosterBio and Pall contribute address a major challenge and current bottleneck in the multi-billion dollar Regenerative Medicine industry. Stem cell-based technologies are progressing rapidly through the clinic, but manufacturing of cellular therapeutics, including hMSCs, is significantly limited in scale. There are few standards or complete solutions currently marketed that enable simple, rapid development of scalable production methods of hMSCs.
The strategic alliance between Pall and RoosterBio will provide total bioprocess solutions for cell culture of low cost, translation-friendly hMSCs for development of Cell Therapy, Tissue Engineering, Drug Screening, and Regenerative Medicine products. Mario Philips, president, single-use technologies, stated, “Our vision is aligned with the customer requirements of large scale stem cell culture. Along with the RoosterBio hMSCs and media, the Pall solution offerings such as XRS 20 and Xpansion multiplate bioreactors, SoloHill microcarriers, and Allegro biocontainers enable our customers to grow stem cells on an industrially relevant scale.”
Jon Rowley, RoosterBio’s Chief Executive & Technical Officer, states: “Our mission at RoosterBio is to greatly increase the availability and accessibility of stem cell technologies to researchers and product developers across the globe. We are excited to be working with Pall and their innovative technology team to develop complete solutions for the simple and affordable generation of industrial quantities of hMSCs. Pall’s global team will be critical in driving rapid adoption of these systems on an international scale. This partnership will have a major impact on the pace of the Regenerative Medicine field.”
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE
Finding a Key to Unlock Blocked Differentiation in microRNA-deficient ESCsNews
Researchers from the University of Alabama at Birmingham have partly solved a long-unanswered question about stem cells - why are pluripotent stem cells that have mutations to block the production of microRNAs unable to differentiate?READ MORE